NewcelX updates presentation to highlight diabetes program collaboration
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
April 20, 2026 7:37 AM EDTZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate presentation that includes the companys strategic collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN) and highlights the advancement of its flagship Type 1 Diabetes program, NCEL-101, as a central pillar of the companys development strategy.
The updated presentation outlines the integration of NewcelXs scalable stem-cell-derived islet replacement platform with Eledons investigational anti-CD40L monoclonal antibody tegoprubart, a... More
